Pharma Focus Asia

Poxel Expands Metabolic Pipeline Through Strategic Acquisition Agreement with DeuteRx for DRX-065, a Novel Clinical Stage Drug Candidate for NASH, and Other Programs

Friday, August 31, 2018

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), and DeuteRx LLC, a privately-held clinical-stage biopharmaceutical company dedicated to improving racemic drugs, today announced that Poxel has acquired DRX-065, a novel clinical stage drug candidate that the company plans to develop for the treatment of NASH. Poxel has also acquired a portfolio of additional deuterated drug candidates from DeuteRx for metabolic, specialty and rare diseases.

Poxel will pay DeuteRx an upfront payment composed of EUR 6.8 million (USD 8 million) in cash plus 1.29 million in new ordinary shares of Poxel common stock, representing 4.99 percent of Poxel’s issued capital. DeuteRx is also eligible to receive development, regulatory and sales-based milestone payments, and royalties on net sales.

“Today’s announcement is strategically important to Poxel and represents the third major corporate transaction that we have accomplished in the past year,” said Thomas Kuhn, CEO of Poxel. “With the partnerships for Imeglimin with Sumitomo Dainippon Pharma and with Roivant Sciences, and the successful completion of the Phase 1 program for PXL770, a direct AMPK activator that we are advancing for the treatment of NASH, together with this important agreement with DeuteRx, we have strengthened the company both financially and strategically. We are very excited about our robust, well-diversified, mid- to late-stage metabolic pipeline targeting large market opportunities, as well as earlier-stage metabolic programs advancing in development.”

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024